Journal article
Can a Single Measurement of Apixaban Levels Identify Patients at Risk of Overexposure? A Prospective Cohort Study
Abstract
Background Patients with atrial fibrillation (AF) are frequently treated with apixaban 2.5-mg twice daily (BID) off-label, presumably to reduce the bleeding risk. However, this approach has the potential to increase the risk of ischemic stroke. If a single measurement could reliably identify patients with high drug levels, the increased stroke risk may be mitigated by confining off-label dose reduction to such patients. Objectives This study …
Authors
de Vries TAC; Hirsh J; Bhagirath VC; Ginsberg JS; Pisters R; Hemels MEW; de Groot JR; Eikelboom JW; Chan NC
Journal
TH Open, Vol. 06, No. 01, pp. e10–e17
Publisher
Thieme
Publication Date
January 2022
DOI
10.1055/s-0041-1740492
ISSN
2567-3459